Rocket Pharmaceuticals financials
$2.59−0.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating income | -$231.7M | -$273.2M | -$259.7M | -$224.3M | -$167.2M | -$134.3M | -$75.9M | -$71.0M |
| Net income | -$223.1M | -$258.7M | -$245.6M | -$221.9M | -$169.1M | -$139.7M | -$77.3M | -$74.5M |
| Net margin | — | — | — | — | — | — | — | — |
| Diluted EPS | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 | $-2.52 | $-1.58 | $-1.89 |
| EBITDA | -$219.6M | -$266.0M | -$254.7M | -$220.4M | -$164.0M | -$133.2M | -$75.5M | -$70.6M |
| Operating cash flow | -$190.0M | -$209.7M | -$194.9M | -$178.1M | -$121.3M | -$74.6M | -$64.7M | -$53.8M |
| Free cash flow | -$190.5M | -$215.6M | -$211.4M | -$186.5M | -$128.9M | -$95.2M | -$87.9M | -$55.2M |
| Diluted shares | 111.1M | 94.8M | 84.0M | 68.1M | 63.2M | 55.4M | 49.0M | 39.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $77.6M | $163.6M | $55.9M | $140.5M | $232.7M | $297.1M |
| Short-term investments | $111.4M | $208.7M | $317.3M | $215.9M | $156.0M | $185.6M |
| Total debt | $21.3M | $21.2M | $21.1M | $21.0M | $20.8M | $60.6M |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M | $590.8M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M | $87.3M |
| Shareholders' equity | $277.2M | $463.2M | $492.6M | $489.7M | $454.7M | $503.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology